An elevated pre-treatment neutrophil to lymphocytes ratio (NLR) is associated with poor prognosis in various malignancies. Optimal cut-off is highly variable across studies and could not be determined individually for a patient to inform his prognosis. We hypothesize that NLR variations could be more useful than baseline NLR to predict progression-free survival (PFS) and overall survival (OS) in patients (pts) receiving anti-PD1 treatment.
Patients and methods
All pts with metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC) who received anti-PD1 nivolumab monotherapy in second-line setting or later were included in this French multicentric retrospective study. NLR values were prospectively collected prior to each nivolumab administration. Clinical characteristics were recorded. Associations between baseline NLR, NLR variations and survival outcomes were determined using Kaplan–Meier’s method and multivariable Cox regression models.
161 pts (86 mRCC and 75 mNSCLC) were included with a median follow-up of 18 months. On the whole cohort, any NLR increase at week 6 was significantly associated with worse outcomes compared to NLR decrease, with a median PFS of 11 months vs 3.7 months (p < 0.0001), and a median OS of 28.5 months vs. 18 months (p = 0.013), respectively. In multivariate analysis, NLR increase was significantly associated with worse PFS (HR 2.2; p = 6.10−5) and OS (HR 2.1; p = 0.005). Consistent results were observed in each cohort when analyzed separately.
Any NLR increase at week 6 was associated with worse PFS and OS outcomes. NLR variation is an inexpensive and dynamic marker easily obtained to monitor anti-PD1 efficacy.
This is a preview of subscription content, log in to check access.
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
Abe H, Kamai T (2013) Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol Off J Jpn Urol Assoc 20(10):944–955. https://doi.org/10.1111/iju.12187
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab vs docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab vs docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab vs everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab vs chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774
Hammers HJ, Plimack ER, Infante JR et al (2017) Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol Off J Am Soc Clin Oncol 35(34):3851–3858. https://doi.org/10.1200/JCO.2016.72.1985
Hellmann MD, Ciuleanu T-E, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. https://doi.org/10.1056/NEJMoa1801946
Michot JM, Bigenwald C, Champiat S et al (1990) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 2016(54):139–148. https://doi.org/10.1016/j.ejca.2015.11.016
Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473. https://doi.org/10.1038/nrclinonc.2016.58
Hallmarks of Cancer: The next generation: cell. https://www.cell.com/cell/fulltext/S0092-8674(11)00127-9?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867411001279%3Fshowall%3Dtrue. Published September 3, 2017. Accessed 3 Sep 2017.
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. https://doi.org/10.1016/j.cell.2010.01.025
Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19(2):203–208. https://doi.org/10.1016/j.coi.2007.02.001
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218(11):1402–1410. https://doi.org/10.1016/j.imbio.2013.06.003
Templeton AJ, McNamara MG, Eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst 106(6):dju124. https://doi.org/10.1093/jnci/dju124
Marchioni M, Primiceri G, Ingrosso M et al (2016) The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer 14(6):473–484. https://doi.org/10.1016/j.clgc.2016.04.008
Bar-Ad V, Palmer J, Li L et al (2016) Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. https://doi.org/10.1007/s12094-016-1593-y
Vano Y-A, Oudard S, By M-A et al (2018) Optimal cut-off for neutrophil-to-lymphocyte ratio: fact or fantasy? A prospective cohort study in metastatic cancer patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0195042
Lalani A-KA, Xie W, Martini DJ et al (2018) Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6(1):5. https://doi.org/10.1186/s40425-018-0315-0
Khunger M, Patil PD, Khunger A et al (2018) Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0197743
Ameratunga M, Chénard-Poirier M, Moreno Candilejo I et al (1990) Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur J Cancer Oxf Engl 2018(89):56–63. https://doi.org/10.1016/j.ejca.2017.11.012
Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer Amst Neth 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013
Kiriu T, Yamamoto M, Nagano T et al (2018) The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0193018
Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer Amst Neth 111:176–181. https://doi.org/10.1016/j.lungcan.2017.07.024
Nakaya A, Kurata T, Yoshioka H et al (February 2018) Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. https://doi.org/10.1007/s10147-018-1250-2
Shiroyama T, Suzuki H, Tamiya M et al (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7(1):13–20. https://doi.org/10.1002/cam4.1234
Becht E, Giraldo NA, Lacroix L et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218. https://doi.org/10.1186/s13059-016-1070-5
Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377(25):2500–2501. https://doi.org/10.1056/NEJMc1713444
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.—PubMed—NCBI. https://www.ncbi.nlm.nih.gov/pubmed/?term=T-cell+invigoration+to+tumour+burden+ratio+associated+with+anti-+PD-1+response. Accessed 22 June 2019.
Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 33(31):3541–3543. https://doi.org/10.1200/JCO.2015.61.6870
Escudier B, Motzer RJ, Sharma P et al (2017) Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol 72(3):368–376. https://doi.org/10.1016/j.eururo.2017.03.037
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081. https://doi.org/10.1093/carcin/bgp127
Kargl J, Busch SE, Yang GHY et al (2017) Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun 8(1):1–11. https://doi.org/10.1038/ncomms14381
Dirican N, Karakaya YA, Gunes S, Daloglu FT, Dirican A (2017) Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer. Clin Respir J 11(6):789–796. https://doi.org/10.1111/crj.12417
The investigators AS, YA had access to the raw data. All authors approved the final manuscript. The corresponding author had full access to all the data, and takes final responsibility for the manuscript submitted for publication.
Conflict of interest
YV, SO, CT and PB: consulting fees from BMS, MSD, Pfizer, Novartis, Ipsen, Roche, Astellas, Sanofi, Janssen. DB: funding to institution for clinical research, advisory role or travel accommodation: Bristol-Meyers Squibb, Pfizer, Roche, Ipsen, MSD, Astra-Zeneca. No potential conflicts of interest were disclosed by the other authors.
Ethics approval and consent to participate
The study was approved by the local institutional review board and was conducted with Good Clinical Practice Guidelines and the Declaration of Helsinki. All patients gave their oral consent. CNIL declaration No 2215794 v 0
Consent for publication
Informed consent for publication has been obtained.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Simonaggio, A., Elaidi, R., Fournier, L. et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother (2020). https://doi.org/10.1007/s00262-020-02637-1